NCT05479721 is a clinical trial in NAFLD, sponsored by University of Oxford.

Who is sponsoring NCT05479721?

NCT05479721 is sponsored by University of Oxford.

What condition does NCT05479721 study?

NCT05479721 studies NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver.

Is NCT05479721 still recruiting?

NCT05479721 is currently active, enrolled. Last updated 16 April 2025.

Last reviewed 2025-04-16 · How we verify

NCT05479721

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LITMUS Imaging Study

Active, enrolled Last updated 16 April 2025

What this trial tests

trial in NAFLD in 450 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

4 September 2019

Primary endpoint
31 October 2025

31 October 2025

Quick facts

Lead sponsor	University of Oxford
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	450
Start date	4 September 2019
Primary completion	31 October 2025
Estimated completion	31 October 2025
Sites	18 locations across France, Italy, Finland, Greece, Sweden, United Kingdom, Germany, Switzerland

Conditions studied

NAFLD — all drugs for NAFLD →
NASH — all drugs for NASH →
NASH - Nonalcoholic Steatohepatitis — all drugs for NASH - Nonalcoholic Steatohepatitis →
Fibrosis, Liver — all drugs for Fibrosis, Liver →

Sponsor

University of Oxford

Who can join

Adults 18 to 100, any sex, with NAFLD or NASH. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against NAFLD histological scores in a cross-sectional analysis and the natural history of NAFLD in a longitudinal study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol.
Pavlides M, Mózes FE, Akhtar S, Wonders K, et al · · 2023 · cited 8× · PMID 37802221 · DOI 10.1016/j.cct.2023.107352

Verify or expand the search:

Other recruiting trials for NAFLD

Currently open trials in the same condition.

NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
NCT06879236 — Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease · recruiting
NCT06888310 — Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease · NA · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05479721 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 16 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05479721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing